Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world.

Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance.

The National Vaccine Program Office in the U.S. Department of Health and Human Services has selected William Schaffner, M.D., to receive its 2017 NVPO UpShot Award in Vaccine Communication.

The Human Vaccines Project and Vanderbilt University Medical Center (VUMC) announced this week that they joined forces with Illumina Inc. to decipher the human immunome, the genetic underpinnings of the immune system.

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017 recipient of the Stanley J. Korsmeyer Award given by the American Society for Clinical Investigation (ASCI), one of the nation’s oldest and most respected honor societies for physician-scientists.

New research from Vanderbilt University eavesdrops on gene expression in human immune system cells before and after vaccination against bird flu.

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.